Cortisol shifts fat to the midsection, and perimenopause amplifies it. What the ashwagandha weight trials actually measured, and how large the effect was.
Maca is non-hormonal and libido-focused, ashwagandha works through cortisol and stamina. A side-by-side look at the perimenopause evidence for each.
Perimenopausal joint pain tracks declining estrogen and rising inflammation. Where ashwagandha’s anti-inflammatory data applies, and where it does not.
The stress response runs through the HPA axis, and ashwagandha appears to blunt its output. How the adaptogenic mechanism is thought to work.
Withanolide absorption, half-life and clearance shape dosing and timing. What is known about how the body actually processes ashwagandha extract.
The recent ashwagandha literature is small, mostly short, and rarely perimenopause-specific. What the newest trials add, and what the gaps still are.
Adaptogens act on the HPA axis and stress signalling rather than on a single receptor. How ashwagandha’s proposed mechanisms actually work.
Ashwagandha raises NK cell activity and immunoglobulin markers in trials. What immune support means in midlife, and who should be cautious about it.
Ashwagandha does not contain or replace estrogen. How its cortisol and thyroid effects can still change how perimenopausal hormone shifts feel.
Ashwagandha shows GABA-mimetic activity in preclinical work, which may explain the calming effect. What that mechanism does and does not prove in humans.
Cortisol is the mechanism most of ashwagandha’s perimenopause reputation rests on. What the trials measured, at what dose, and over what timeframe.
Withanolides are the steroidal lactones behind most of ashwagandha’s measured activity. Which ones matter, and why extract type changes the profile entirely.